|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Business Group from 1999 to April 2006
and thereafter also as our Chief Operating Officer until she resigned from such
positions in May 2007, played a central role in all Stock Option Committee
grants. Ms. Dai participated in the
selection of grant dates with the benefit of hindsight and signed false minutes
and other employee related corporate documents. The Special Committee also
found that she failed to establish proper internal controls and failed to
exercise proper review and inquiry as an officer. Certain individuals involved in the process
said that they did not feel able to provide her with frank advice. She signed inaccurate external documents,
including 10-K’s and proxy statements.
She did not personally benefit from any of the grants she approved.
Dr. Sehat Sutardja, Marvell’s Chairman of the Board, President and Chief Executive Officer, was found to have had a limited role in the stock option process and to have participated in only a few instances in awards with incorrect measurement dates with respect to which he had received no or inadequate advice. He signed inaccurate external documents, including our SEC filings, financial statements, and proxy statements. The Special Committee found that he failed to establish proper internal controls and that certain individuals involved in the process to some extent did not feel able to provide him with frank advice. He did not personally benefit from any of the grants he approved. This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Business Group from 1999 to April 2006
and thereafter also as our Chief Operating Officer until she resigned from such
positions in May 2007, played a central role in all Stock Option Committee
grants. Ms. Dai participated in the selection of grant dates with the benefit of
hindsight and signed false minutes and other employee related corporate
documents. The Special Committee also found that she failed to establish proper
internal controls and failed to exercise proper review and inquiry as an
officer. Certain individuals involved in the process said that they did not
feel able to provide her with frank advice. She signed inaccurate external
documents, including 10-K’s and proxy statements. She did not personally benefit from any of
the grants she approved.
Dr. Sehat Sutardja, Marvell’s Chairman of the Board, President and Chief Executive Officer, was found to have had a limited role in the stock option process and to have participated in only a few instances in awards with incorrect measurement dates with respect to which he had received no or inadequate advice. He signed inaccurate external documents, including our SEC filings, financial statements, and proxy statements. The Special Committee found that he failed to establish proper internal controls and that certain individuals involved in the process to some extent did not feel able to provide him with frank advice. He did not personally benefit from any of the grants he approved. This excerpt taken from the MRVL 10-Q filed Jul 2, 2007. Business Group from 1999 to April 2006
and thereafter also as our Chief Operating Officer until she resigned from such
positions in May 2007, played a central role in all Stock Option Committee
grants. Ms. Dai participated in the
selection of grant dates with the benefit of hindsight and signed false minutes
and other employee related corporate documents. The Special Committee also
found that she failed to establish proper internal controls and failed to
exercise proper review and inquiry as an officer. Certain individuals involved in the process
said that they did not feel able to provide her with frank advice. She signed inaccurate external documents,
including 10-K’s and proxy statements.
She did not personally benefit from any of the grants she approved.
Dr. Sehat Sutardja, Marvell’s Chairman of the Board, President and Chief Executive Officer, was found to have had a limited role in the stock option process and to have participated in only a few instances in awards with incorrect measurement dates with respect to which he had received no or inadequate advice. He signed inaccurate external documents, including our SEC filings, financial statements, and proxy statements. The Special Committee found that he failed to establish proper internal controls and that certain individuals involved in the process to some extent did not feel able to provide him with frank advice. He did not personally benefit from any of the grants he approved. | EXCERPTS ON THIS PAGE:
RELATED TOPICS for MRVL: |
| |||||||
